{"id":827508,"date":"2025-03-19T09:04:01","date_gmt":"2025-03-19T13:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/"},"modified":"2025-03-19T09:04:01","modified_gmt":"2025-03-19T13:04:01","slug":"case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/","title":{"rendered":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence"},"content":{"rendered":"

<\/p>\n

Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence<\/b><\/p>\n

Case Demonstrates CyPath\u00ae Lung\u2019s Potential in Guiding Oncological Care<\/i><\/b><\/p>\n

SAN ANTONIO–(BUSINESS WIRE<\/a>)–bioAffinity Technologies<\/b><\/a>, Inc. (Nasdaq: BIAF; BIAFW) <\/b>today released a study<\/a> of a complex clinical case in which CyPath\u00ae Lung\u2019s<\/a> real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient.\n<\/p>\n

\n\u201cThis case exemplifies how CyPath\u00ae Lung can play a crucial role not only in lung cancer diagnostics but also in broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures,\u201d bioAffinity Technologies\u2019 President and Chief Executive Officer Maria Zannes said.\n<\/p>\n

\nThe patient, a former smoker with COPD who was treated successfully for breast cancer in 2019, was under surveillance for lung cancer due to her history. A routine low-dose CT scan detected indeterminate nodules, including an eight-millimeter non-calcified nodule in her left upper lung lobe. \u201cGiven her risk factors and the fact that I\u2019ve been following her with CT scans, this finding was very worrisome,\u201d Gordon H. Downie, MD, PhD, Director of the Pulmonary Nodule Clinic at Titus Regional Medical Center in Mount Pleasant, Texas, said.\n<\/p>\n

\nTraditional diagnostic approaches presented challenges. A PET scan was unlikely to provide clarity due to the lesion’s small size, and serum markers were contraindicated because of her prior cancer. \u201cThe CyPath\u00ae Lung test afforded me the ability in real time to assess a small nodule in a high-risk patient,\u201d Dr. Downie said. \u201cThe result was likely malignant which launched an aggressive, forward-looking diagnostic approach.\u201d\n<\/p>\n

\nRecognizing the patient’s history, her care team conducted a follow-up mammogram, which revealed a new breast cancer confirmed by biopsy.\n<\/p>\n

\n\u201cEach case study underscores the benefit of adding CyPath\u00ae Lung to the standard of care for evaluating indeterminate lung nodules,\u201d Zannes said. \u201cBy providing earlier and more accurate diagnostic insights, CyPath\u00ae Lung can help reduce the need for costly, invasive follow-up procedures, ultimately lowering healthcare costs while improving patient outcomes. This growing body of evidence strengthens the case for broader adoption of CyPath\u00ae Lung, highlighting the significant financial and clinical benefits of our technology.\u201d\n<\/p>\n

\nA study<\/a> published in the Journal of Health Economics Outcomes and Research and authored by pulmonologists Michael Morris, MD, and Sheila Habib, MD, found that an average cost savings of $2,773 per patient would have been achieved in 2022 if CyPath\u00ae Lung had been part of the standard of care for Medicare patients with a positive lung cancer screening, for a total of $379 million. The study attributes the savings to a reduction in follow-up diagnostic assessments, expensive follow-up procedures and procedure-related complications. The study also found that adding CyPath\u00ae Lung to the standard of care for private-payer patients with a positive lung cancer screening result could have saved even more, an average of $6,460 per patient, an estimated total savings of $895 million if all individuals screened in 2022 were covered by private insurance.\n<\/p>\n

About CyPath\u00ae Lung<\/b><\/p>\n

\nCyPath\u00ae<\/sup> Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results<\/a> demonstrated that CyPath\u00ae Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com<\/a>.\n<\/p>\n

About bioAffinity Technologies, Inc.<\/b><\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CyPath\u00ae Lung playing a crucial role in lung cancer diagnostics and broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures, and adding CyPath\u00ae Lung to the standard of care for indeterminate nodules lowering healthcare costs for both Medicare and private payers. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of CyPath\u00ae Lung to increase diagnostic accuracy, lower healthcare costs, and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250319645782\/en\/<\/a><\/span><\/p>\n

bioAffinity Technologies
\n<\/b>
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com<\/a><\/p>\n

Investor Relations
\n<\/b>
Dave Gentry
\n
RedChip Companies Inc.
\n
1-800-RED-CHIP (733-2447) or 407-491-4498
\n
BIAF@redchip.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Data Management Biotechnology Technology Health Oncology Health Technology Other Science Medical Devices Software Artificial Intelligence Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence Case Demonstrates CyPath\u00ae Lung\u2019s Potential in Guiding Oncological Care SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath\u00ae Lung\u2019s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient. \u201cThis case exemplifies how CyPath\u00ae Lung can play a crucial role not only in lung cancer diagnostics but also in broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures,\u201d bioAffinity Technologies\u2019 President and Chief Executive Officer Maria Zannes said. The patient, a former smoker with COPD who was treated successfully … <\/p>\n

Continue reading “Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827508","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCase Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence Case Demonstrates CyPath\u00ae Lung\u2019s Potential in Guiding Oncological Care SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath\u00ae Lung\u2019s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient. \u201cThis case exemplifies how CyPath\u00ae Lung can play a crucial role not only in lung cancer diagnostics but also in broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures,\u201d bioAffinity Technologies\u2019 President and Chief Executive Officer Maria Zannes said. The patient, a former smoker with COPD who was treated successfully … Continue reading "Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-19T13:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence\",\"datePublished\":\"2025-03-19T13:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/\"},\"wordCount\":1066,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/\",\"name\":\"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-19T13:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/","og_locale":"en_US","og_type":"article","og_title":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk","og_description":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence Case Demonstrates CyPath\u00ae Lung\u2019s Potential in Guiding Oncological Care SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath\u00ae Lung\u2019s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient. \u201cThis case exemplifies how CyPath\u00ae Lung can play a crucial role not only in lung cancer diagnostics but also in broader oncological decision-making, helping to guide clinical strategies and improve patient outcomes while reducing risky invasive procedures,\u201d bioAffinity Technologies\u2019 President and Chief Executive Officer Maria Zannes said. The patient, a former smoker with COPD who was treated successfully … Continue reading \"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-19T13:04:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence","datePublished":"2025-03-19T13:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/"},"wordCount":1066,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/","name":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-19T13:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250319645782r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/case-study-bioaffinity-technologies-positive-cypath-lung-result-leads-to-detecting-breast-cancer-recurrence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Case Study: bioAffinity Technologies\u2019 Positive CyPath\u00ae Lung Result Leads to Detecting Breast Cancer Recurrence"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827508"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}